From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein-Templated Synthesis

14Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Multitarget directed ligands (MTDLs) are arising as promising tools to tackle complex diseases. The main goal of this work is to create powerful modulating agents for neurodegenerative disorders. To achieve this aim, we have combined fragments that inhibit key protein kinases involved in the main pathomolecular pathways of Alzheimer's disease (AD) such as tau aggregation, neuroinflammation and decreased neurogenesis, whilst looking for a third action in beta-secretase (BACE1), responsible of β-amyloid production. We obtained well-balanced MTDLs with in vitro activity in three different relevant targets and efficacy in two cellular models of AD. Furthermore, computational studies confirmed how these compounds accommodate adequately into the long and rather narrow BACE1 catalytic site. Finally, we employed in situ click chemistry using BACE1 as protein template as a versatile synthetic tool that allowed us to obtain further MTDLs.

Cite

CITATION STYLE

APA

Nozal, V., García-Rubia, A., Cuevas, E. P., Pérez, C., Tosat-Bitrián, C., Bartolomé, F., … Martínez, A. (2021). From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer’s Disease using Protein-Templated Synthesis. Angewandte Chemie - International Edition, 60(35), 19344–19354. https://doi.org/10.1002/anie.202106295

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free